Glucagon like peptide-1: A new therapeutic target for diabetes mellitus

Indian Journal of Pharmacology

Volumn 38, Issue 4, 2006, Pages 231-237

  Patel, S ^a   Goyal, R ^b   Anand, I ^a   Shah, J ^a   Patel, H ^a   Patel, C ^a  

^a Shri Sarvajanik Pharmacy College   (India)

^b L M COLLEGE OF PHARMACY   (India)

Author keywords

Exendin 4; NIDDM

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; CJC 1131; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; ISOLEUCINE THIAZOLIDIDE; LIRAGLUTIDE; LY 307161; METFORMIN; SULFONYLUREA; TE 999011; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE; VILDAGLIPTIN;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN RELEASE; NERVE CELL GROWTH; NERVE CELL PLASTICITY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRURITUS; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE;

EID: 33747605065     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.27018     Document Type: Review

References (86)

1. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106:329-33.
2. Perry TA, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword? Tren Pharmacol Sci 2003;24:377-83.
3. Kieffer TJ. GIP or not GIP? That is the question. Tren Pharmacol Sci 2003;24:110-12.
4. Doyle ME, Egan JM. Glucagon-like peptide-1. Prog Hoem Res 2001;56:377-99.
5. Drucker DJ. Minireview: the glucagons-like peptides. Endocrinology 2001;142:521-7.
6. Todd JF. Glucagon-like peptide-1(GLP-1): A trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27:533-6.
7. Deacon CF. Degradation of glucagon-like peptide-1 by human plasma invitro yields as N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7.
8. Kundsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-35.
9. Kieffer TJ. Degradation of glucose dependent insulinotropic polypeptide and truncated glucagon- like-peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-96.
10. 2 terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
11. Egan JM. glucagon- like-peptide-1 augments insulin mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002:87;3768-73.
12. Perfetti R. Glucagon-like petide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-05.
13. Thorens B. Expression cloning of the pancreatic beta cell receptor for the glucoincretin hormone glucagon- like-peptide-1. Proc Natl Acad Sci 1992;89:8641-5.
14. Drucker DJ. Glucagon- like-peptide I stimulates insulin gene expression and increase cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci 1987;84:3434-38.
15. Doyle ME, Egan JM. Pharmacological agents that directly modulates insulin secretion. Pharmacol Rev 2003;55:105-31.
16. Perry T. A novel neurotrophic property of glucagon-like-peptide 1 a promoter of nerve growth factor mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-66.
17. Perry T, Greig NH. Glucagon-like peptide: A new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis 2002;4:487-96.
18. Buteau J. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphotidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta(INS-1)-cells. Diabetologia 1999;42:856-64.
19. Zhou J. Glucagon-like peptide 1 and expedin-4 convert pancreatic ARA2J cells into glucagons- and insulin-producing cells. Diabetes 1999;48:2358-66.
20. Leech CA. Expression of cAMP- regulated guanine nucleotide exchange factors in pancreatic beta-cells. Biochem Biophys Res Commun 2000;278:44-7.
21. Kawasaki H. A family of cAMP- binding proteins that directly activate Rap1. Science 1998;282:2275-9.
22. Weir GC. Glucagon-like peptide-I(7-37) actions on endocrine pancreas. Diabetes 1989;38:338-42.
23. Fehmann HC, Habener JF. Insulinotropic hormone glucagons-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992;130:159-66.
24. Stoffers DA. Insulinotropic glucagons-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000;49:741-8.
25. Orskov C. Effect of truncated glucagons-like peptide-1[proglucagon-(78- 107) amide] on endocrine secretion from pig pancreas, antrum and nonantral stomach. Endocrinology 1988;123:2009-13.
26. Nauck MA. Effects of glucagon-like-peptide 1 on counteregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46.
27. Dunning BE, Foley JE, Ahren B. GLP-1 does not inhibit glucagon release in response to hypoglycemia. Diabetologia 2005;48:1700-13.
28. Layer P. Ileal release of glucagons-like peptide-1(GLP0-1) Association with inhibition og gastric acid secretion in humans. Dig Dis Sci 1995;40:1074-82.
29. Nauck MA. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physio 1997;273:981-8.
30. Goke R. Distribution of Glp-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995;7:2294-300.
31. Shughrue PJ. Glucagon-like peptide-1 receptor(GLP1-R) mRNA in the rat hypothalamus. Endocrinology 1996;137:5159-62.
32. Turton MD. A role for glucagon-like-peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
33. Calvo, JC. Structural characterization by affinity croos linking of glucagon-like peptide-1(7-36) amide receptor in rat brain. J neurochem 1995;64:299-306.
34. Campos RV. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994;134:2156-64.
35. Orskov C. Glucagon like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon like peptide 1. Diabetes 1996;45:832-5.
36. Flint A. Glucagon-like peptide 1 promotes swatiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-20.
37. Toft-Nielsen MB. Continuous subcutaneous infusion of glucagons-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137-43.
38. Scrocchi LA. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like-peptide 1 receptor gene. Nat Med 1996;2:1254-58.
39. Scrocchi LA, Drucker DJ. Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like-peptide-1 receptor-/- mice. Endocrinology 1998;143:4397-408.
40. Farilla L. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408.
41. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002;45:1263-73.
42. Hui H. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-55.
43. Perry T. Protection and reversal of excitotoxic damage by glucagon-like-peptide-1 and exendin-4. J Pharmacol Ex Ther 2002;302:881-8.
44. Cheng B. Neurotrophin-4/5 protects hippocampal and cortical neurons against energy deprivation- and excitatory amino acid-induced injury. Brain Res 1994;650:331-5.
45. Oka J, Suzuki E, Kondo Y. Endogenous GLP-1 is involved in beta-amyloid protein-induced memory impairment and hippocampal neuronal death in rats. Brain Res 2000;878:194-8.
46. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. A novel neurotrophic property of glucagon-like Peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-66.
47. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003;72:603-12.
48. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like Peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881-8.
49. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003;9:1173-9.
50. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous GLP-1 (7-36 amide) in type 2 diabetic patients. Diabetologia 1993;36:741-4.
51. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998;21:1925-31.
52. Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53.
53. Carolyn F. Therapeutic Strategies Based on Glucagon-Like Peptide 1. Diabetes 2004;53:2181-9.
54. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
55. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 2001;30:935-82.
56. Kathleen, Dungan MD, John B. Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide. Clin Diabetes 2005;23:56-62.
57. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 2001;281:155-61.
58. Vilsboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4.
59. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999;42:45-50.
60. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000;141:1936-41.
61. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002;51:1443-52.
62. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 2002;45:1263-73.
63. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-70.
64. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9.
65. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol 2003;284:1072-9.
66. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonlyurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7.
67. Rautmann ME, Chen CF, Chappell J, Danaberg J, Patterson B, Klausmann G, et al. LY307161 SR, a long-scting GLP-1 analog, improved glycemic control in patients with type 2 diabetes. Diabetes 2003;52:136.
68. Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002;51:424-9.
69. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003;140:123-32.
70. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, et al. The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-91.
71. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-94.
72. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42.
73. Lawrence B, Drefus JF, Wen S, Guivarc'h PH, Drucker DJ, Castaigne JP. CJC-1131, a long-scting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Diabetes 2003;52:125.
74. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003;52:751-9.
75. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 1998;47:764-9.
76. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isuleucine thiazolidide. Diabetes 1998;47:1253-8.
77. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999;42:1324-31.
78. Ahrén B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000;404 :239-45,
79. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci 2000;97:6874-9.
80. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002;51:943-50.
81. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic- hyperinsulinemic clamp study. Diabetes 2002;51:2677-83.
82. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002;51:1461-9.
83. Rothenburg P, Kalbag J, Smith H, Gingerich R, Nedelman J, Villhauer E, et al. Treatment with a DPP-IV inhibitor, NVP-DPP728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans (Abstract). Diabetes 2000;49:39.
84. Ahrén B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75.
85. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84.
86. El-Ouaghlidi A, Rehring ER, Schweizer A, Holmes D, Nauck MA. The dipeptidyl peptidase IV inhibitor, LAF237 does not accentuate reactive hypoglycaemia caused by the sulphonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diabetes 2003;52:118.